Compare Merck & Co., Inc. (MRK) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Prologis Inc — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while Prologis Inc trades at $149.1 (market cap $137.50B). The key difference: Merck & Co., Inc. is far larger — about 2.2× Prologis Inc's market cap, and Prologis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals.
| MRK | PLD | |
|---|---|---|
Market Cap | $307.25B | $137.50B |
Sector | Health | Real Estate |
52-Week High | $129.52 | $149.96 |
52-Week Low | $77.60 | $104.08 |
Enterprise Value | $350.66B | $172.18B |
Dividend Yield | 2.73% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
PLD trades at $149.94, up 0.15% with a bullish technical outlook. The stock shows strong fundamentals with revenue growth to $8.79B in 2025 and a net income margin of 45.79%. Recent Q2 2026 earnings beat expectations, and analyst consensus is positive with a $156.56 price target. The company is actively pursuing acquisition opportunities, as seen in recent Segro takeover attempts.
The outlook for PLD remains favorable due to consistent earnings beats and strategic expansion. Key risks include high valuation multiples and integration challenges from potential acquisitions. Institutional ownership is increasing, supporting a bullish sentiment, though investors should monitor debt levels which have risen to 37.2% of assets in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
